Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Sangamo Therapeutics (SGMO) Equity Ratio (2016 - 2025)

Sangamo Therapeutics has reported Equity Ratio over the past 16 years, most recently at 0.24 for Q4 2025.

  • Quarterly results put Equity Ratio at 0.24 for Q4 2025, down 206.6% from a year ago — trailing twelve months through Dec 2025 was 0.24 (down 206.6% YoY), and the annual figure for FY2025 was 0.24, down 206.6%.
  • Equity Ratio for Q4 2025 was 0.24 at Sangamo Therapeutics, down from 0.07 in the prior quarter.
  • Over the last five years, Equity Ratio for SGMO hit a ceiling of 0.76 in Q1 2023 and a floor of 0.24 in Q4 2025.
  • Median Equity Ratio over the past 5 years was 0.51 (2022), compared with a mean of 0.41.
  • Biggest five-year swings in Equity Ratio: surged 49.0% in 2023 and later tumbled 206.6% in 2025.
  • Sangamo Therapeutics' Equity Ratio stood at 0.52 in 2021, then increased by 0.85% to 0.52 in 2022, then dropped by 4.38% to 0.5 in 2023, then crashed by 55.32% to 0.22 in 2024, then tumbled by 206.6% to 0.24 in 2025.
  • The last three reported values for Equity Ratio were 0.24 (Q4 2025), 0.07 (Q3 2025), and 0.2 (Q2 2025) per Business Quant data.